01/01/2014 - 31/12/2017
Bladder cancer incidence in Spain is among the highest in the world and a leading cause of deaths from cancer in men. Initial treatment is transurethral resection, although Bacillus Calmette-Guérin (BCG) immunotherapy has proved to be the local treatment that is most effective in reducing recurrence and limiting progression. Since the exact mechanisms and molecular mediators of tumour control after BCG treatment are unknown, there is no reliable predictor of response. An early marker of response would be invaluable, as it would prevent comorbidities, reduce mortality and avoid the cost associated with ineffective treatment. The study aim is to identify predictors of response to BCG treatment and design new therapeutic strategies.
